Other related webinars
Are Genes Patentable in the United States? (A Re...
Friday, 26th August, 2011
Time : 02:00 PM | 11:00 AM
GLP Regulations – A Simplified Overview for Ac...
Friday, 2nd December, 2011
Time : 02:00 PM | 11:00 AM
Understanding FDA Guidance on GLP for Nonclinica...
Thursday, 22nd December, 2011
Time : 02:00 PM EST | 11:00 AM PST
FDA and EMA successful development and approvals...
Friday, 22nd June, 2012
Time : 02:00 PM EST | 11:00 AM PST
Strategic insights into European (CHMP/EMA) and ...
Monday, 3rd December, 2012
Time : 02:00 PM EST | 11:00 AM PST
FDA Approvals and Insights: Understanding US-FDA...
Friday, 1st March, 2013
Time : 02:00 PM IST | 09:30 AM CET
Effective Responses to FDA Warning Letters on Qu...
Friday, 15th August, 2014
Time : 01:00 PM | 10:00 AM
FDA’s view of Purchasing Controls, regulatory ...
Friday, 3rd October, 2014
Time : 01:00 PM EST | 10:00 AM PST
A review of the FDA’s oversight, regulatory re...
Friday, 16th January, 2015
Time : 01:00 PM EST | 10:00 AM PST
Preparing for and Managing EU Notified Bodies Au...
Thursday, 28th January, 2016
Time : 01:00 PM EDT | 10:00 AM PDT
Biopharmaceutical Method Transfer – Using a Qu...
Friday, 20th May, 2016
Time : 01:00 PM EDT | 10:00 AM PDT
Quality systems for Analytical Instrumentation a...
Friday, 24th June, 2016
Time : 01:00 PM EDT | 10:00 AM PDT
Effective Investigation of Deviations & Putting ...
Friday, 2nd September, 2016
Time : 04:00 PM IST | 11:30 AM BST
NO More Written Procedure (Standard Operating Pr...
Friday, 14th October, 2016
Time : 01:00 PM EDT | 10:00 AM PDT
Best Practices in Supplier Management: Evaluatio...
Friday, 20th January, 2017
Time : 10:00 AM EST | 04:00 PM BST
Using Quality Indicators for Successful FDA QSR ...
Friday, 10th February, 2017
Time : 04:00 PM IST | 11:30 AM BST
Effective Management Reviews for FDA and Managem...
Friday, 21st April, 2017
Time : 01:00 PM EDT | 10:00 AM PDT
FDA Internal Audits - An Important Tool for Avoi...
Friday, 30th June, 2017
Time : 04:00 PM IST | 11:30 AM BST
FDA Regulatory Rules for Supply Chain and Manufa...
Friday, 4th August, 2017
Time : 11:00 AM EDT | 08:00 AM PDT
FDA - Training Modules
Friday, 28th September, 2018
Time : Set the Time | Set the Time
FDA Quality Systems Inspection Technique (QSIT) ...
Friday, 26th October, 2018
Time : 01:00 PM EDT | 10:00 AM PST
Key Element of Quality Management System Complia...
Friday, 30th August, 2019
Time : 04:00 PM IST | 11:30 AM BST
A CAPA Primer - Elements of a CAPA Program
Friday, 28th February, 2020
Time : 01:00 PM EST | 10:00 AM PST
How To Respond To FDA 483s
Wednesday, 2nd March, 2022
Time : 01:00 PM EST | 10:00 AM PST
FDA Expectations from Supplier Management for GM...
Friday, 22nd April, 2022
Time : 01:00 PM EDT | 10:00 AM PDT
The clinical, regulatory and business challenges...
Friday, 19th August, 2022
Time : 01:00 PM EST | 10:30 AM PST
The FDA CGMP and Data Integrity in Pharmaceutica...
Friday, 7th April, 2023
Time : 01:00 PM EST | 10:30 AM PST
FDA PMA Submissions - Contents, Process, Pitfall...
Friday, 21st April, 2023
Time : 01:00 PM IST | 10:00 AM PST
Complaint Handling in Compliance with FDA and IS...
Thursday, 22nd August, 2024
Time : 01:00 PM EST | 10:00 AM PST
Recorded Webinar
The FDA CGMP and Data Integrity in Pharmaceuticals
timelapse 60 Min with 15 Min QnA of Q and A
Note:
This webinar occured in the past
Along with recorded webinar, copy of presentation slides will be shared
Recorded Webinar can be played unlimited times
Speaker/Presenter
Short Abstract
This Webinar will help your firm to remain in good compliance with the US FDA. Discussion will include methods for maintaining a continuous quality improvement program thereby keeping your site ready for regulatory inspections all of the time.
Potential Negative Consequences of not Complying with CGMP Regulations
If you receive a Warning Letter or you firm is placed on the Import Alert List: you may have to stop manufacturing, recall your products, train all of your employees, validate your manufacturing processes, validate your testing methods and re-qualify your equipment. You will also be required to hire consultants.
This will cost you millions of dollars and could take several years to re-start your production. You will not obtain any new NDA or ANDA approvals and you will not be able to submit any changes to your already approved applications. Your stock price will go down. You may lose your customers and you may have to close your facilities.
This presentation will also include a summary of recent Warning Letters and Import Alerts issues to Indian Pharma.
Key Areas Covered During the Webinar:
- You will learn these Good Compliance Practices from a former FDA Investigator and CDER Compliance Officer
- This Webinar will help your firm to remain in Good Compliance with the US FDA
- Discussion will include methods for maintaining a continuous quality improvement program
- Provide methods for avoiding FDA-483 observations
- Good Practices on how to verbally respond to FDA-483 observations during the exit meeting
- You will learn the potential negative consequences of not complying with CGMP regulations
- This presentation will also include a summary of recent Warning Letters and Import Alerts issues
- Learning from competitors mistakes will prevent you from making these same mistakes
Content Disclaimer
Contents in our website are from external websites. Links to and content from external website are provided for the convenience of users. Biopractice.com takes no responsibility for the content of such links and websites.